Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research

BMC Neurology

Volumn 11, Issue , 2011, Pages

  Cysique, Lucette A ^a,b,c   Waters, Edward K ^d   Brew, Bruce J ^a,b,c  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c St Vincent's Centre for Applied Medical Research   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; VIRUS RNA;

ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL ASSESSMENT; COGNITION; COMORBIDITY; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEARNING; LUMBAR PUNCTURE; MEMORY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBSERVATIONAL METHOD; PSYCHOMOTOR ACTIVITY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TREATMENT DURATION; VIRUS LOAD; REVIEW; VIROLOGY;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CEREBROSPINAL FLUID; HIV INFECTIONS; HUMANS;

EID: 81455161610     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-11-148     Document Type: Article

References (40)

1. Wright E. Neurocognitive impairment and neuroCART. Curr Opin HIV AIDS 2011, 2011:5.
2. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69(18):1789-1799. 10.1212/01.WNL.0000287431.88658.8b, 17914061.
3. Lanoy E, Guiguet M, Bentata M, Rouveix E, Dhiver C, Poizot-Martin I, Costagliola D, Gasnault J. Survival after neuroAIDS: association with antiretroviral CNS Penetration-Effectiveness score. Neurology 2011, 76(7):644-651. 10.1212/WNL.0b013e31820c3089, 21248274.
4. Antiretroviral therapy. , http://www.who.int/hiv/topics/treatment/en/
5. ASHM Proceedings Report - Antiretroviral Guidelines Consensus Discussion (2010). ASHM: 2010; Sydney, Australia 2010, ASHM, 375382, 16789083, ASHM., http://www.ashm.org.au/default2.asp?active_page_id=252
6. Dahl V, Josefsson L, Palmer S. HIV reservoirs, latency, and reactivation: Prospects for eradication. Antiviral Res 2009, 4:4.
7. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007, 21(14):1915-1921. 10.1097/QAD.0b013e32828e4e27, 17721099.
8. Cunningham P, Smith D, Satchell C, Cooper DA, Brew B. Evidence for independant development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000, 14:1949-1954. 10.1097/00002030-200009080-00010, 10997399.
9. Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S, Price RW. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 1999, 13:1051-1061. 10.1097/00002030-199906180-00008, 10397535.
10. Strain MC, Letendre S, Pillai SK, Russell T, Ignacio CC, Gunthard HF, Good B, Smith DM, Wolinsky SM, Furtado M, et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. Journal of Virology 2005, 79(3):1772-1788. 10.1128/JVI.79.3.1772-1788.2005, 544082, 15650202.
11. Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. Journal of Virology 2004, 78(18):10133-10148. 10.1128/JVI.78.18.10133-10148.2004, 515019, 15331746.
12. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997, 71(3):2059-2071. 191294, 9032338.
13. Berman NG, Parker RA. Meta-analysis: neither quick nor easy. BMC Med Res Methodol 2002, 2(10):10. 122061, 12171604.
14. Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 2011, 76(8):693-700. 10.1212/WNL.0b013e31820d8b0b, 3053326, 21339496.
15. Finney DJ. A statistician looks at met-analysis. J Clin Epidemiol 1995, 48(1):87-103; discussion 105-108. 10.1016/0895-4356(94)00096-9, 7853052.
16. Hoenig JM, Heisey DM. The Abuse of Power: The Pervasive Fallacy of Power Calculations for Data Analysis. The American Statistician 2001, 55(1):1-6.
17. Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behavior Research Methods 2009, 41(4):1149-1160. 10.3758/BRM.41.4.1149, 19897823.
18. Cohen J. Statistical power analysis for the behavioral sciences 1988, New York: Academic Press, 2.
19. Cochran WG. Sampling Techniques 1977, Wiley Inc.
20. Cysique L, Maruff P, Brew B. The neuropsychological profile of symptomatic, AIDS and ADC patients in the pre-HAART era: a meta-analysis. Journal of the International Neuropsychological Society 2006, 12:1-15.
21. Cysique LA, Brew BJ. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 2009, 19(2):169-185. 10.1007/s11065-009-9092-3, 19424802.
22. May S, Letendre S, Haubrich R, McCutchan JA, Heaton R, Capparelli E, Ellis R. Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in neuroAIDS. J Neuroimmune Pharmacol 2007, 2(1):97-104. 10.1007/s11481-006-9057-8, 18040832.
23. Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Greenberg RN, Berger JR. Neuroimaging correlates of HIV-associated BBB compromise. J Neuroimmunol 2004, 157(1-2):140-146. 10.1016/j.jneuroim.2004.08.025, 15579291.
24. Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010, 75(10):864-873. 10.1212/WNL.0b013e3181f11bd8, 2938971, 20702792.
25. Antinori A, Giancola ML, Grisetti S, Soldani F, Alba L, Liuzzi G. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS 2002, 16:1867-1876. 10.1097/00002030-200209270-00003, 12351946.
26. Chang L, Ernst T, Witt MD, Ames N, Walot I, Jovicich J, DeSilva M, Trivedi N, Speck O, Miller EN. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antivir Ther 2003, 8(1):17-26.
27. Cysique L, Maruff P, Brew B. Antiretroviral therapy in HIV infection: are neurologically active drugs important?. Archives of Neurology 2004, 61(11):1699-1704. 10.1001/archneur.61.11.1699, 15534181.
28. Cysique LA, Maruff P, Brew BJ. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients. Neurology 2006, 66(9):1447-1450. 10.1212/01.wnl.0000210477.63851.d3, 16682686.
29. Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, McCutchan JA, Heaton RK, Ellis RJ. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009, 73(5):342-348. 10.1212/WNL.0b013e3181ab2b3b, 2725933, 19474412.
30. De Luca A, Ciancio BC, Larussa D, Murri R, Cingolani A, Rizzo MG, Giancola ML, Ammassari A, Ortona L. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology 2002, 59:342-347.
31. Eggers C, Hertogs K, Sturenburg HJ, van Lunzen J, Stellbrink HJ. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. Aids 2003, 17(13):1897-1906. 10.1097/00002030-200309050-00008, 12960822.
32. Marra CM, Lockhart D, Zunt JR, Perrin M, Coombs RW, Collier AC. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology 2003, 60:1388-1390. 2683839, 12707454.
33. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. Aids 2009, 23(11):1359-1366. 10.1097/QAD.0b013e32832c4152, 2706549, 19424052.
34. Letendre S, McCutchan J, Childers M, Woods S, Lazzaretto D, Heaton R, Grant I, Ellis R, . Group. H Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Annals of Neurology 2004, 56(3):416-423. 10.1002/ana.20198, 15349869, Group. H.
35. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008, 65(1):65-70. 10.1001/archneurol.2007.31, 2763187, 18195140.
36. Patel K, Ming X, Williams PL, Robertson KR, Oleske JM, Seage GR. Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents. Aids 2009, 23(14):1893-1901. 10.1097/QAD.0b013e32832dc041, 2821205, 19644348.
37. Sacktor N, Tarwater PM, Skolasky RL, McArthur J, Selnes OA, Becker J, Cohen B, Miller EN. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology 2001, 57:542-544.
38. Sevigny JJ, Albert SM, McDermott MP, McArthur JC, Sacktor N, Conant K, Schifitto G, Selnes OA, Stern Y, McClernon DR, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004, 63:2084-2090.
39. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011, 25(3):357-365. 10.1097/QAD.0b013e32834171f8, 21124201.
40. Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J Acquir Immune Defic Syndr 2009, 52(1):56-63. 10.1097/QAI.0b013e3181af83d6, 19731418.